Abstract
Background DNA-launched vaccine is “manufactured” in vaccinated individuals and does not require traditional vaccine manufacturing facility and technology. Goals. Using yellow fever 17D vaccine, we have provided proof-of-concept evidence that these vaccine can be launched from DNA and induce specific immune responses against pathogenic virus causing yellow fever. The infectious DNA vaccine technology is based on the transcription of the full-length genomic RNA of the live-attenuated virus from plasmid DNA in vitro and in vivo. A few ng of infectious DNA encoding the fulllength genomic RNA are required to initiate the replication of the vaccine virus in vitro. The in vivo-generated viral RNA initiates limited replication of the vaccine virus, which in turn leads to efficient immunization. Electroporation in vivo has induced specific immune responses against pathogenic virus and protected mice against fatal disease. Here we describe a novel infectious DNA vaccine technology which combines advantages of naked DNA vaccination and live-attenuated vaccine efficacy. Conclusions If successful in further testing, this technology can dramatically change the way we make vaccines as well as vaccination practice.
Highlights
DNA-launched vaccine is “manufactured” in vaccinated individuals and does not require traditional vaccine manufacturing facility and technology
Comparative characteristics of live attenuating vaccine (LAV), traditional DNA vaccines and vaccines obtained by the technology of iDNA®
При условии дальнейшего совершенствования состава ДНК и путей введения вакцины на основе инфекционной ДНК (иДНК) штамма YF17D эти препараты могут стать альтернативой применяемым в настоящее время аттенуированным вакцинам, отличаясь стабильностью, простотой производства и контроля качества
Summary
Представить обзор результатов разработки технологии вакцины против желтой лихорадки на основе инфекционной ДНК, сочетающих преимущества вакцин на основе депротеинизированной ДНК и живых аттенуированных вакцин. А.А.Ishmukhametov*, , 2,3 P.P. Bredenbeek, I.S. Lukashevich Medigen, Inc., Frederick, MD, USA 2 Federal State Budget Institution of Science «Chumakov Federal Scientific Center for Research and Development of Immune-andBiological Products of Russian Academy of Sciences», Moscow, Russia 3 Sechenov First Moscow State Medical University, of the Ministry of Health of the Russian Federation, Moscow, Russia 4 Department of Medical Microbiology, Center of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands 5 Department of Pharmacology and Toxicology, School of Medicine, Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, NIH Regional Bio-containment Laboratory, University of Louisville, USA
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
